Last10K.com

Paratek Pharmaceuticals, Inc. (PRTK) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2019

Paratek Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1516551 Ticker: PRTK
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2019
Oct. 31, 2019
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Period End DateSep. 30, 2019 
Document Fiscal Year Focus2019 
Document Fiscal Period FocusQ3 
Trading SymbolPRTK 
Entity Registrant NamePARATEK PHARMACEUTICALS, INC. 
Entity Central Index Key0001178711 
Entity Current Reporting StatusYes 
Current Fiscal Year End Date--12-31 
Entity Filer CategoryAccelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity File Number001-36066 
Entity Tax Identification Number33-0960223 
Entity Address, Address Line One75 Park Plaza 
Entity Address, City or TownBoston 
Entity Address, State or ProvinceMA 
Entity Address, Postal Zip Code02116 
City Area Code617 
Local Phone Number807-6600 
Entity Common Stock, Shares Outstanding 33,287,946
Entity Interactive Data CurrentYes 
Title of 12(b) SecurityCommon Stock, par value $0.001 per share 
Security Exchange NameNASDAQ 
Entity Incorporation, State or Country CodeDE 
Document Quarterly Reporttrue 
Document Transition Reportfalse 

View differences made from one quarter to another to evaluate Paratek Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Paratek Pharmaceuticals, Inc..

Continue

Assess how Paratek Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Paratek Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Cash Flow
Expense
Other
Inside Paratek Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited)
Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)
Capital Stock
Capital Stock - Additional Information (Detail)
Cash And Cash Equivalents And Marketable Securities
Cash And Cash Equivalents And Marketable Securities (Tables)
Cash And Cash Equivalents And Marketable Securities - Additional Information (Detail)
Cash And Cash Equivalents And Marketable Securities - Summary Of Available For Sale Securities (Detail)
Commitments And Contingencies
Description Of The Business
Description Of The Business - Additional Information (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Schedule Of Financial Assets And Liabilities Measured At Fair Value (Detail)
Fixed Assets, Net
Fixed Assets, Net (Tables)
Fixed Assets, Net - Schedule Of Fixed Assets, Net (Detail)
Income Taxes
Income Taxes - Additional Information (Detail)
Inventories, Net
Inventories, Net (Tables)
Inventories, Net - Schedule Of Inventories (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Summary Of Future Minimum Operating Lease Obligations Under Non-Cancelable Operating Leases (Detail)
Leases - Summary Of Lease Costs Recognized Under Topic 842 And Other Information (Detail)
License And Collaboration Agreements
License And Collaboration Agreements - Additional Information (Detail)
Long-Term Debt
Long-Term Debt (Tables)
Long-Term Debt - Additional Information (Detail)
Long-Term Debt - Schedule Of Future Principal Payments (Detail)
Long-Term Debt - Summary Of Debt (Detail)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Antidilutive Shares Excluded From Computation Of Diluted Net Income (Loss) Per Share (Detail)
Other Accrued Expenses
Other Accrued Expenses (Tables)
Other Accrued Expenses - Schedule Of Other Accrued Expenses (Detail)
Recent Accounting Pronouncements
Recent Accounting Pronouncements - Additional Information (Detail)
Restricted Cash
Restricted Cash (Tables)
Restricted Cash - Additional Information (Detail)
Restricted Cash - Summary Of Reconciliation Of Cash, Cash Equivalents, And Restricted Cash Reported Within Condensed Consolidated Statement Of Cash Flows (Detail)
Stock-Based And Incentive Compensation
Stock-Based And Incentive Compensation (Tables)
Stock-Based And Incentive Compensation - Additional Information (Detail)
Stock-Based And Incentive Compensation - Schedule Of Share-Based Compensation, Rsu, Activity (Detail)
Stock-Based And Incentive Compensation - Schedule Of Share-Based Compensation, Stock Options, Activity (Detail)
Stock-Based And Incentive Compensation - Schedule Of Share-Based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail)
Stock-Based And Incentive Compensation - Summary Of Stock-Based Compensation Expense Included In Company's Condensed Consolidated Statements Of Operations And Comprehensive Loss (Detail)
Summary Of Significant Accounting Policies And Basis Of Presentation
Summary Of Significant Accounting Policies And Basis Of Presentation (Policies)
Summary Of Significant Accounting Policies And Basis Of Presentation (Tables)
Summary Of Significant Accounting Policies And Basis Of Presentation - Additional Information (Detail)
Summary Of Significant Accounting Policies And Basis Of Presentation - Summary Of Product Revenue Allowance And Reserve Categories (Detail)

Material Contracts, Statements, Certifications & more

Paratek Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: PRTK
CIK: 1178711
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-042902
Submitted to the SEC: Tue Nov 12 2019 11:06:56 AM EST
Accepted by the SEC: Tue Nov 12 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/prtk/0001564590-19-042902.htm